First Interstate Bank grew its holdings in shares of Celgene Co. (NASDAQ:CELG) by 5.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,448 shares of the biopharmaceutical company’s stock after acquiring an additional 5,202 shares during the quarter. Celgene comprises 3.3% of First Interstate Bank’s investment portfolio, making the stock its 4th largest position. First Interstate Bank’s holdings in Celgene were worth $15,377,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Thompson Davis & CO. Inc. raised its holdings in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI increased its stake in Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the period. Guidant Wealth Advisors purchased a new position in Celgene in the 3rd quarter worth approximately $119,000. Motco increased its stake in Celgene by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the period. Finally, Penserra Capital Management LLC purchased a new position in Celgene in the 2nd quarter worth approximately $129,000. Hedge funds and other institutional investors own 78.93% of the company’s stock.
Shares of Celgene Co. (NASDAQ CELG) traded up $1.49 during trading hours on Friday, hitting $92.51. The stock had a trading volume of 10,465,217 shares, compared to its average volume of 8,240,000. The company has a market capitalization of $69,580.00, a P/E ratio of 25.63, a P/E/G ratio of 0.66 and a beta of 1.49. The company has a debt-to-equity ratio of 2.29, a quick ratio of 3.52 and a current ratio of 4.99. Celgene Co. has a 1 year low of $88.32 and a 1 year high of $147.17.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.09. The firm had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The company’s quarterly revenue was up 16.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.61 earnings per share. sell-side analysts expect that Celgene Co. will post 7.68 EPS for the current year.
A number of equities analysts have commented on the company. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price target on the stock in a research note on Thursday, January 25th. Mizuho set a $128.00 price target on Celgene and gave the stock a “buy” rating in a research note on Tuesday, December 26th. William Blair reissued an “outperform” rating on shares of Celgene in a research note on Friday, October 20th. BTIG Research reissued a “hold” rating on shares of Celgene in a research note on Tuesday, January 23rd. Finally, BidaskClub raised Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $130.35.
In other news, insider Mark J. Alles acquired 3,260 shares of Celgene stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the transaction, the insider now owns 178,904 shares in the company, valued at $16,441,277.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.95% of the stock is currently owned by corporate insiders.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.